checksurshorts: career positions earlier were 15 and now down to 13.
getting ready for ma which i think they believe feb 2016 since they will start buying shares at any price feb 01 2016.
chmp meeting jan 25-28 2016 with meeting minutes released friday jan 29 2016.
monday will be feb 01 2016.
Total Number of Shares Held 60,327,261 ==
Large Block Owners 126 ==
Percent Shares Owned 96.90% ==
Percent Change in Ownership 0.00% ==
2.40% Brokerage Firms ==
93.30% Investment Managers ==
1.20% Strategic Entities ==
3.10% Non-Institutional ==
Regional Holdings ==
North America 93.50% ==
Europe 2.80% ==
Asia 0.40% ==
Monthly Share Rotation ==
Type Number of Shares Value of Change Shares Outstanding ==
Buyers 11/18/15 390 $7,738 0.00% ==
Sellers 11/18/15 898 $17,816 0.00% ==
could it look like insider information? looking at will lewis answer price does not matter.
why would it matter what the share price is when all shares and options were free to trade.
next to last sentence I would expect to personally apply our Insmed shares during the next four quarters regardless of price.
who is our?
from will lewis.
I believe now as I did when I first joined three years ago that the best days of this company will be realized from now through the medium term simply by executing on the opportunities that are directly in front of us. As a consequence, I intend to put in place the 10b5-1 stock purchase plan as I have previously done. Under the plan, I would expect to personally apply our Insmed shares during the next four quarters regardless of price. Further information regarding my plan will be available in the future 8-K filing.
tried to be a trader one year. come tax time a lot of work trying to sort out gains and losses. nothing much gained. true traders would not be on this board.
true traders have all sorts of information which include sometimes insider.high speed computers and someone else's money to trade with.
down to 14 positions today.
yesterday there were 16.
must have filled 4making it 12and then adding back 2 more positions.
Manager/Associate Director Regulatory CMC regulatory affairs.
Director, Global Marketing commercialization.
ramping up hiring again.
is it possible for us to gain early medicine access under the new revised guidelines.
ema regulatory tools for early access to medicines.
do a search on ema regulatory tools for early access to medicines
contains information about reaching market authorization within 150 days of application.
July 24 2015.
went all the way to $28.66 and now back to $16.34
could be wrong but the 11.5 million shares sold for $237.5 million dollars at $20.65 are at a loss now.
unless they ran it up and now shorting the hell out of it now before any news which seems to
take the sp down good or bad news.
what a loss they have been taking bending over.
why not do this? big profit if can get away with it.
hope this was not plans for some close friends
Ritu Baral - Cowen and Company
Hi, guys. Sorry about dropping off. I had one more follow-up question unless Liisa asked it ahead of me. It seems like the responses for the 100-day questions you’re taking a bit longer than as we expected. Are there any surprises in those questions around the NTM possibility? Is there any more color you can give us to why this is taking a bit longer than we’re used to?
Will Lewis - President and CEO
Will Lewis - President and CEO
No, and that is design, so I appreciate the question. To refresh everyone’s recollection, the 112 study which forms the basis for the evaluation of our application had a one-year patient follow up, which finished up in sort of the third quarter of this year, give or take. And the CSR that is written at the tail end of the completion of this study had to be done. Now that we have that one-year data and it is so compelling, it’s really critical that we get that final data included in the CSR. So when we originally went back to the EMA, we requested the six months to be able to submit by the end of the calendar year so that we could include that CSR from the 112
study. That’s a really important point. Everything else is ready to go. That particular CSR has got to be in the dataset.
insmhistorian I would give it a surf's up for sure. only problem is the surf is full of big great white sharks circling in at every chance they get. will end soon.
thought the same thing few weeks back when they would drive the price down $.50 or more with 1-2-3 share trades for several days. who can do this?
at least now they use 100 share trades. same results just not as obvious unless you see the levlel 2 trade.
like this sentence out of article. could not post but was under yahoo finance headlines
That= relief= rally,= which= Stockton= sees= occurring= in =the- next- couple -of- weeks,- could= find= itself moving= all- the- way =up=to- the- 200=day -moving- average,- currently =at= $74.94= per =share.
paragraph from article. can not post article address without being deleted.
Only one of the six leading causes of death — chronic obstructive pulmonary disease — didn’t drop. Rates of death from COPD doubled despite a decline in deaths among men near the end of the study period.
how many of these deaths were misdiagnosed NTM as copd?